Memantine Demo

Memantine, the active ingredient in Memantine Demo, is an NMDA receptor antagonist presented as an unknown strength/oral dosage form for oral use. It is used in the treatment of Alzheimer’s disease in adults.

GNH USA supplies Memantine Demo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is indicated for neurodegenerative conditions where excessive NMDA receptor activity contributes to neuronal injury.

Alzheimer’s disease (mild to moderate): helps maintain cognitive function and daily activities. Alzheimer’s disease (moderate to severe): supports functional abilities and may slow decline. Alzheimer’s disease (any stage): used as part of a comprehensive management plan to improve quality of life.

Memantine may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: transient light‑headedness, especially after dose initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, manageable with diet or laxatives. - Confusion: occasional disorientation, typically improves over time. - Fatigue: feeling unusually tired, may lessen with dose adjustment. - Hypertension: modest increase in blood pressure in some patients.

Serious or Rare Side Effects: - Seizures: rare occurrence, requires immediate medical attention. - Cardiac arrhythmia: irregular heart rhythm, potentially life‑threatening. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hallucinations or psychosis: visual or auditory disturbances. - Suicidal thoughts: emergent mood changes needing urgent evaluation. - Liver function abnormalities: elevated enzymes detected on labs.

Before initiating memantine therapy, several safety considerations should be reviewed.

Renal impairment: assess kidney function and adjust dose if necessary. History of seizures: monitor closely for increased seizure activity. Cardiovascular disease: evaluate blood pressure and cardiac status regularly. Concurrent NMDA antagonists: avoid combined use to prevent additive CNS effects. Pregnancy and lactation: safety not established; weigh potential risks and benefits. Store at room temperature: keep in the original container, protect from moisture and light.

Memantine can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Amantadine: combined NMDA blockade may intensify central nervous system effects. - Ketamine: additive antagonism can lead to severe neuropsychiatric reactions. - High‑dose anticholinergics: may worsen cognitive impairment.

Moderate Interactions (Monitor Closely): - Diuretics: may increase risk of hypotension. - Antihypertensives: additive blood‑pressure‑lowering effect. - CNS depressants (e.g., benzodiazepines): may enhance dizziness and sedation.